Clinical Significance of Circulating Tumor Cells and Free DNA in Non-small Cell Lung Cancer

被引：0

作者：

Isobe, Kazutoshi ^{[1
]}

Hata, Yoshinobu ^{[2
]}

Kobayashi, Kunihiko ^{[3
]}

Hirota, Nao ^{[1
]}

Sato, Keita ^{[1
]}

Sano, Go ^{[1
]}

Sugino, Keishi ^{[1
]}

Sakamoto, Susumu ^{[1
]}

Takai, Yujiro ^{[1
]}

Shibuya, Kazutoshi ^{[1
]}

Takagi, Keigo ^{[2
]}

Homma, Sakae ^{[1
]}

机构：

[1] Toho Univ, Omori Med Ctr, Dept Resp Med, Ota Ku, Tokyo 1438541, Japan

[2] Toho Univ, Omori Med Ctr, Dept Chest Surg, Ota Ku, Tokyo 1438541, Japan

[3] Saitama Med Univ, Saitama Int Med Ctr, Dept Resp Med, Hidaka City, Saitama, Japan

来源：

ANTICANCER RESEARCH | 2012年 / 32卷 / 08期

关键词：

Circulating tumor cells (CTCs); circulating free DNA (cfDNA); lung cancer; epidermal growth factor receptor (EGFR); CellSearch system; Cycleave real-time PCR assay; FACTOR RECEPTOR MUTATIONS; PROSTATE-CANCER; EGFR MUTATION; PHASE-III; GEFITINIB; SURVIVAL; BLOOD; SERUM; CARBOPLATIN/PACLITAXEL; PROGRESSION;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: This pilot study assessed correlations between circulating tumor cells (CTCs) and circulating free DNA (cfDNA) of metastatic non-small cell lung cancer (NSCLC) after acquisition of resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Patients and Methods: CTCs were counted using the CellSearch system (Veridex). cfDNA was analyzed for EGFR mutation status by the Cycleave real-time PCR assay. Results: Twenty-four patients participated in this study. CTCs were detected in 8 of 24 cases (33.3%), at a mean of 2.6 CTCs per 7.5 ml blood (range: 1-24). EGFR mutations in cfDNA were detected in 6 out of 24 cases (25%). The EGFR imitation detection rates in cfDNA were significantly higher in patients with CTCs per 7.5 ml (100%) than in those with <2 CTCs per 7.5 ml (10%) (p=0.0001). Conclusion: The presence of CTCs was correlated with the positivity of EGFR mutation in cfDNA.

引用

页码：3339 / 3344

页数：6

共 32 条

[1] Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
Allard, WJ
Matera, J
Miller, MC
Repollet, M
Connelly, MC
Rao, C
Tibbe, AGJ
Uhr, JW
Terstappen, LWMM
[J]. CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6897 - 6904
[2] American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
Azzoli, Christopher G.
Baker, Sherman, Jr.
Temin, Sarah
Pao, William
Aliff, Timothy
Brahmer, Julie
Johnson, David H.
Laskin, Janessa L.
Masters, Gregory
Milton, Daniel
Nordquist, Luke
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Reily
Smith, Thomas J.
Strawn, John R.
Trent, David
Giaccone, Giuseppe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6251 - 6266
[3] Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer
Bai, Hua
Mao, Li
Wang, Hang Shu
Zhao, Jun
Yang, Lu
An, Tong Tong
Wang, Xin
Duan, Chun Jian
Wu, Na Mei
Guo, Zhi Qing
Liu, Yi Xu
Liu, Hong Ning
Wang, Ye Yu
Wang, Jie
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2653 - 2659
[4] Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Cohen, Steven J.
Punt, Cornelis J. A.
Iannotti, Nicholas
Saidman, Bruce H.
Sabbath, Kert D.
Gabrail, Nashat Y.
Picus, Joel
Morse, Michael
Mitchell, Edith
Miller, M. Craig
Doyle, Gerald V.
Tissing, Henk
Terstappen, Leon W. M. M.
Meropol, Neal J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) : 3213 - 3221
[5] Circulating tumor cells, disease progression, and survival in metastatic breast cancer
Cristofanilli, M
Budd, GT
Ellis, MJ
Stopeck, A
Matera, J
Miller, MC
Reuben, JM
Doyle, GV
Allard, WJ
Terstappen, LWMM
Hayes, DF
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) : 781 - 791
[6] Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer
Donev, Ivan S.
Wang, Wei
Yamada, Tadaaki
Li, Qi
Takeuchi, Shinji
Matsumoto, Kunio
Yamori, Takao
Nishioka, Yasuhiko
Sone, Saburo
Yano, Seiji
[J]. CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2260 - 2269
[7] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Engelman, Jeffrey A.
Zejnullahu, Kreshnik
Mitsudomi, Tetsuya
Song, Youngchul
Hyland, Courtney
Park, Joon Oh
Lindeman, Neal
Gale, Christopher-Michael
Zhao, Xiaojun
Christensen, James
Kosaka, Takayuki
Holmes, Alison J.
Rogers, Andrew M.
Cappuzzo, Federico
Mok, Tony
Lee, Charles
Johnson, Bruce E.
Cantley, Lewis C.
Janne, Pasi A.
[J]. SCIENCE, 2007, 316 (5827) : 1039 - 1043
[8] Non Small Cell Lung Cancer
Ettinger, David S.
Akerley, Wallace
Bepler, Gerold
Blum, Matthew G.
Chang, Andrew
Cheney, Richard T.
Chirieac, Lucian R.
D'Amico, Thomas A.
Demmy, Todd L.
Ganti, Apar Kishor P.
Govindan, Ramaswamy
Grannis, Frederic W., Jr.
Jahan, Thierry
Jahanzeb, Mohammad
Johnson, David H.
Kessinger, Anne
Komaki, Ritsuko
Kong, Feng-Ming
Kris, Mark G.
Krug, Lee M.
Le, Quynh-Thu
Lennes, Inga T.
Martins, Renato
O'Malley, Janis
Osarogiagbon, Raymond U.
Otterson, Gregory A.
Patel, Jyoti D.
Pisters, Katherine M.
Reckamp, Karen
Riely, Gregory J.
Rohren, Eric
Simon, George R.
Swanson, Scott J.
Wood, Douglas E.
Yang, Stephen C.
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (07): : 740 - +
[9] Fehm T, 2002, CLIN CANCER RES, V8, P2073
[10] Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Fukuoka, Masahiro
Wu, Yi-Long
Thongprasert, Sumitra
Sunpaweravong, Patrapim
Leong, Swan-Swan
Sriuranpong, Virote
Chao, Tsu-Yi
Nakagawa, Kazuhiko
Chu, Da-Tong
Saijo, Nagahiro
Duffield, Emma L.
Rukazenkov, Yuri
Speake, Georgina
Jiang, Haiyi
Armour, Alison A.
To, Ka-Fai
Yang, James Chih-Hsin
Mok, Tony S. K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) : 2866 - 2874

← 1 2 3 4 →